740
-1.99%
Close of 9 Nov 2026, in IDR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kalbe Farma Tbk PT
Its shares trade on IDX under the ticker KLBF.JK. It has been listed since 30 July 1991. In the fiscal year to 31 December 2025, it reported revenue of IDR 35.32trn and net income of IDR 3.66trn. At that date it held total assets of IDR 30.70trn and shareholders' equity of IDR 23.31trn.
PT Kalbe Farma Tbk engages in the development, distribution, and trading of pharmaceutical products. The company is headquartered in Jakarta, Dki Jakarta. Its business is classified into four segments: prescription drugs, health products, nutritional products as well as distribution and logistics. Its prescription drugs segment manufactures unbranded generic, branded generic and patented drugs. Its health products segment offers over-the-counter (OTC) therapeutic drugs, consumer health products as well as energy and health drinks; some major brands under the segment are Woods, Procold, Extra Joss and Hydro Coco. Its nutritional products segment manufactures a range of products for infants, toddlers, children, teenagers, adults, expectant and lactating mothers as well as elderly; some of major brands under the segment are Prenagen, Milna, Diabetasol and Entrasol. The distribution and logistics segment is operated through its subsidiary, PT Enseval Putera Megatrading Tbk.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Jul 1991
- Employees
- 12,427
- Website
- kalbe.co.id ↗
Leadership
Pay as last reported
- Ms. Bernadette Ruth Irawati SetiadyPresident Commissioner, since 1997
- Mr. .. VidjongtiusPresident Director
- Mr. Mulialie ..Director
- Mr. Jos Iwan AtmadjajaDirector
- Mr. Sie DjohanDirector
- Ms. Kartika SetiabudyDirector
- Mr. Bernadus Karmin WinataDirector
- Mr. Ronny HadianaCommissioner
- Mr. Santoso OenCommissioner, since 2000
- Mr. Budi Dharma WreksoatmodjoCommissioner, since 1992
- Ms. Lilis HalimIndependent Commissioner
- Prof. Rhenald KasaliIndependent Commissioner
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 88
- Social
- 90
- Governance
- 69
- Direct emissions (scope 1)
- 18,484.77 t
- Energy emissions (scope 2)
- 75,530.4 t
- Women in the workforce
- 33%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Market Presence: Kalbe Farma Tbk PT has a strong and well-recognized presence in the pharmaceutical industry, with a wide range of products and a large customer base.
- Diversified Product Portfolio: The company offers a diverse range of pharmaceutical, consumer health, and nutrition products, reducing its dependence on specific markets or product categories.
- Strong Research and Development (R&D) Capabilities: Kalbe Farma Tbk PT invests significantly in R&D activities, allowing the company to innovate and introduce new products, which can drive growth and maintain competitiveness.
Weaknesses
- Dependence on Domestic Market: While Kalbe Farma Tbk PT has a strong presence in the domestic market, the company's dependence on it makes it vulnerable to changes in the local economic and regulatory conditions.
- Limited International Presence: The company's international operations are limited compared to its domestic operations, which could hinder its growth potential in global markets.
- High Competition: The pharmaceutical industry is highly competitive, with numerous local and international players. Kalbe Farma Tbk PT faces intense competition, which could affect its market share and profitability.
Opportunities
- Growing Healthcare Market: The increasing awareness and expenditure on healthcare provide opportunities for Kalbe Farma Tbk PT to expand its customer base and introduce new products to meet the rising demand.
- Expansion into Emerging Markets: Exploring untapped markets in emerging economies can help the company diversify its revenue streams and reduce dependence on its domestic market.
- Strategic Partnerships and Collaborations: Forming partnerships and collaborations with other pharmaceutical companies or research institutions can lead to shared resources, knowledge exchange, and potential breakthroughs.
Threats
- Regulatory Challenges: Stringent regulations and changing government policies can pose challenges to Kalbe Farma Tbk PT's operations, affecting product approvals, pricing, and market entry barriers.
- Counterfeit Products: The presence of counterfeit pharmaceutical products in the market can undermine the company's brand reputation and erode customer trust.
- Cost and Pricing Pressures: Increasing production costs and price controls imposed by governments or healthcare systems can impact profitability and squeeze profit margins.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.